Clinical significance of breast cancer susceptibility gene 1 expression in resected non-small cell lung cancer: A meta-analysis

Table 1 Basic characteristics of included studies

Ref.	Year	Country	Sample size	Positive, n (%)	TNM stage	Outcome	Source of HR	NOS score
Rosell et al[18]	2007	Spain	123	40 (32.5)	IB-IIIA	OS	R	6
Bartolucci et al[11]	2009	Italy	54	36 (66.7)	IB-IIB	OS/DFS	R	7
Ma et al[19]	2010	China	89	53 (59.6)	IIIA	OS/DFS	E	8
Leng et al[20]	2012	China	85	14 (16.5)	I- IV	OS/DFS	R	7
Gachechiladze et al[21]	2013	Israel	32	9 (28.1)	I- II	OS/DFS	E	7
Gachechiladze et al[21]	2013	Israel	58	15 (25.9)	III- IV	OS/DFS	E	7
Yu et al[22]	2013	China	80	36 (45)	I- IV	OS/DFS	E	7
Grossi et al[23]	2015	Italy	81	45 (55.6)	I A-IIIB	OS	R	6
Lafuente-Sanchis et al[24]	2015	Spain	64	30 (46.9)	I	DFS	R	7
Huang et al[12]	2016	China	84	11 (13.1)	II-III	DFS	R	8
Wang et al[25]	2017	China	70	NR	II-III	OS	R	6
Levallet et al[26]	2017	France	221	129 (58.4)	I- IV	OS/DFS	R	8

TNM: Tumor-node-metastasis; OS: Overall survival; DFS: Disease-free survival; HR: Hazard ratio; R: Reported; E: Estimated; NOS: Newcastle-Ottawa quality assessment scale.

Table 2 Correlations of breast cancer susceptibility gene 1 expression with clinicopathological characteristics in resected non-small cell lung cancer

Ref.	Gender (M vs F)	Age (≥ 60 vs < 60)	Tumor size (T3/4 vs T1/2)	TNM stage (III /IV vs I/II)	Histology (AC vs SCC)	Differentiation (poor vs moderate/well)
Rosell et al[18]	-	-	-	-		-
Bartolucci et al[11]	-	-	-	-		-
Ma et al[19]	1.050 (0.740-1.489)	-	1.046 (0.734-1.489)	-	0.916 (0.636-1.319)	1.204 (0.860-1.687)
Leng et al[20]	-	-	-	-	-	-
Gachechiladze et al[21]	-	-	-	0.920 (0.454-1.861)	-	-
Gachechiladze et al[21]	0.857 (0.608-1.210)	1.273 (0.917-1.768)	-	1.020 (0.727-1.433)	0.990 (0.704-1.392)	1.238 (0.890-1.723)
Yu et al[22]	-	-	-	-	-	-
Grossi et al[23]	-	-	-	-	-	-
Lafuente-Sanchis et al[24]	0.829 (0.265-2.592)	0.367 (0.050-2.678)	-	3.375 (0.776-14.678)	1.660 (0.383-7.204)	-
Huang et al[12]	-	-	-	-	-	-
Wang et al[25]	0.948 (0.735-1.224)	0.889 (0.711-1.112)	-	-	-	-
Overall	0.94 (0.79-1.12), P = 0.522; I2 = 0.0, P = 0.871	1.01 (0.72-1.42), P = 0.948; I2 = 51.2, P = 0.129	-	1.05 (0.78-1.42), P = 0.739; I2 = 22.7, P = 0.274	0.97 (0.76-1.24), P = 0.806; I2 = 0.0, P = 0.732	1.22 (0.97-1.55), P = 0.097; I2 = 0.0, P = 0.908

M: Male; F: Female; TNM: Tumor-node-metastasis; AC: Adenocarcinoma; SCC: Squamous cell carcinoma.

Table 3 Meta-analysis for association of breast cancer susceptibility gene 1 expression with survival of resected esophageal squamous cell carcinoma patients

Analysis	No. of studies	HR (95%CI)	Log-rank P value	I2 (%)	P value
Overall survival	10	1.60 (1.25-2.05)	< 0.001	0	0.794
Country
Non-Asian countries	4	1.57 (1.15-2.15)	0.005	0.0	0.798
Asian countries	6	1.66 (1.12-2.45)	0.011	7.5	0.495
Disease-free survival	9	1.78 (1.42-2.23)	< 0.001	0.0	0.781
Country
Non-Asian countries	3	1.58 (1.13-2.20)	0.007	22.3	0.276
Asian countries	6	1.97 (1.44-2.69)	< 0.001	0.0	0.936

HR: Hazard ratio.